stockrow
Saturday 7 November 2026
Export BDTX’s income statement to Excel — free account
Black Diamond Therapeutics, Inc.
BDTX Healthcare Biotechnology
Black Diamond Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.0 million.
- EPS
- +10.5%
- Free cash flow
- +12.9%
Quarter to June 2026, against a year earlier
1.73
0.07
+4.22%
Follow BDTX
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
8.72 | 8.18 | 8.14 | 6.98 | |
Current Ratio |
8.94 | 8.42 | 8.46 | 7.28 | |
Net Debt/EBITDA |
12.44 | 7.33 | 10.53 | 9.19 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.92 | 0.45 | 1.13 | 0.80 | |
Capex/Depreciation |
0.01 | 0.05 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.14) | (0.12) | (0.18) | (0.14) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.14) | (0.12) | (0.18) | (0.14) | |
Cash per Share |
2.38 | 2.26 | 2.07 | 1.93 | |
Shareholders Equity per Share |
2.22 | 1.97 | 1.82 | 1.68 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.22 | 1.97 | 1.82 | 1.68 | |
Free Cash Flow |
(7.85) | (6.78) | (10.23) | (7.97) | |
Working Capital |
123.45 | 116.71 | 108.43 | 99.55 | |
Capital Expenditures |
0.00 | 0.00 | — | — | |
Net Current Asset Value |
107.41 | 101.64 | 94.35 | 86.46 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
1.47 | 2.29 | 2.80 | 1.09 | |
Average Assets |
147.81 | 132.83 | 154.58 | 145.71 | |
Average Common Equity |
111.79 | 97.75 | 122.91 | 114.35 |
Columns are period end dates · fundamentals updated 26 Oct 2026